Ranbaxy to implement Instem's Provantis preclinical software suite at Gurgaon R&D center in India

May 9 2014

Instem, a leading provider of IT solutions to the global early development healthcare market, is pleased to announce that Ranbaxy Laboratories Limited (Ranbaxy) has purchased the Provantis® preclinical software suite to automate laboratory processes at their R&D Headquarters in Gurgaon, India.

Ranbaxy is a research based international pharmaceutical company serving customers in over 150 countries. Ranbaxy develops, manufactures and markets generic, branded generic, value-added and Over-the-Counter (OTC) products, Anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates. The company also carries out new, innovative research.

Ranbaxy's continued focus on research & development has resulted in several regulatory approvals in both developed and emerging markets, including the development of India's first New Chemical Entity (NCE), Synriam^TM, a new age cure for Malaria.

Key facts

• Ranbaxy to implement Provantis 9, the latest version of Instem's market leading preclinical software solution
• Comprehensive suite of integrated Provantis modules to be deployed, including Inlife, Pathology, Tables & Statistics, Clinical Pathology, Protocol & Report Assembly
• Provantis to replace in-house developed applications to streamline processes and further improve productivity
• A range of professional services purchased to facilitate quicker, smoother implementation and faster return on investment
• Provantis software to provide enhanced compliance capabilities

Provantis will be delivering demonstrable efficiency improvements to Ranbaxy at its Gurgaon R&D center in India and will offer enhanced compliance capabilities, integrated reporting and reduced QC burden.

Instem's VP Global Sales, Europe & Asia, Neil Donaldson, commented "We are delighted to welcome Ranbaxy as our newest client in the Asia Pacific region and look forward to a long and successful partnership. Instem recognizes the increasingly important role that Indian organizations play in the global pharmaceutical market and we are committed to supporting the future growth and development of the Indian R&D community."

Instem entered the early drug development market in India during 2005 when they welcomed their first Indian customer, Advinus Therapeutics. Instem maintains a physical presence in the region through its office in Pune.